Arbutus Biopharma
ABUS
ABUS
53 hedge funds and large institutions have $118M invested in Arbutus Biopharma in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
38% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 21
39% less call options, than puts
Call options by funds: $106K | Put options by funds: $175K
Holders
53
Holding in Top 10
1
Calls
$106K
Puts
$175K
Top Buyers
| 1 | +$4.7M | |
| 2 | +$838K | |
| 3 | +$359K | |
| 4 |
Invesco
Atlanta,
Georgia
|
+$321K |
| 5 |
TI
Telemetry Investments
New York
|
+$244K |
Top Sellers
| 1 | -$1.75M | |
| 2 | -$1.1M | |
| 3 | -$573K | |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$469K |
| 5 |
Goldman Sachs
New York
|
-$398K |